[1] Abe H, Matsubara T, Iehara N, et al. Type Ⅳ collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation[J]. J Biol Chem, 2004, 279:14201-14206. [2] Mima A, Arai H, Matsubara T, et al. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy[J]. Diabetes,2008, 57:1712-1722. [3] Li Q, Feng L, Li J, et al. Urinary Smad1 is a new biomarker for diagnosis and evaluating the severity of diabetic nephropathy[J]. Endocrine, 2014,46:83-89. [4] Fu WJ, Fang YG, Deng RT, et al. Correlation of high urinary Smad1 level with glomerular hyperfiltration in type 2 diabetes mellitus[J]. Endocrine, 2013,43:346-350. [5] Tominaga T, Abe H, Ueda O, et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy[J]. J Biol Chem,2011,286:20109-20116. [6] Abe H, Tominaga T, Matsubara T, et al. Scleraxis modulates bon morphogenetic protein4 (BMP4)-Smad1 protein-smooth muscle-actin (SMA) signal transductionin in diabetic nephropathy[J]. J Biol Chem, 2012,287:20430-20442. [7] Lan HY.Transforming growth factor-beta/Smad signalling in diabetic nephropathy[J]. Clin Exp Pharmacol Physiol, 2012, 39: 731-738. [8] Moustakas A, Souchelnytskyi S, Heldin CH.Smad regulation in TGF-beta signal transduction[J]. J Cell Sci, 2001,114:4359-4369. [9] Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases[J]. Kidney Int, 1996,49:461-469. [10] Ji HK,Kim BK,Moon KC, et al. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis[J]. Kidney Int,2003,64:1715-1721. [11] Cheon PH,Xu ZG,Sorae C,et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy[J]. Nephrol Dial Transplant, 2003,18:1115-1121. [12] Letizia Z, Anthony GW. Norden C, et al. A more tubulocentric view of diabetic kidney disease[J]. J Nephrol,2017, 30: 701-717. [13] Upton PD, Long L, Trembath RC, et al. Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells[J]. Mol Pharmacol,2008,73:539-552. [14] Nakamura T, Ushiyama C, Suzuki S, et al, Urinary excretion of podocytes in patients with diabetic nephropathy[J]. Nephrol Dial Transplant, 2000,15:137913-137983. |